Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
94 hedge funds and large institutions have $435M invested in Avadel Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 30 increasing their positions, 19 reducing their positions, and 9 closing their positions.
278% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 9
58% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 19
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
32% more funds holding
Funds holding: 71 → 94 (+23)
31% more capital invested
Capital invested by funds: $332M → $435M (+$103M)
41% less call options, than puts
Call options by funds: $910K | Put options by funds: $1.53M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.51M |
| 2 |
CM
Castleark Management
Chicago,
Illinois
|
+$8.52M |
| 3 |
Millennium Management
New York
|
+$6.58M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$6.32M |
| 5 |
MACM
March Altus Capital Management
Greenwich,
Connecticut
|
+$5.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$18.3M |
| 2 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$12.7M |
| 3 |
PC
PointState Capital
New York
|
-$5.72M |
| 4 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
-$3.62M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.3M |
AVDL Hedge Fund Activity: Q4 2014 in Review
94 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q4 2014, worth a combined $435M — up 31% from $332M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new AVDL positions and 9 closed out — a net gain of 25 holders — while 30 added to existing stakes and 19 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $9.51M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $18.3M sold.
- 94 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q4 2014, up from 71 in Q3 2014.
- Funds reported $435M of Avadel Pharmaceuticals stock for Q4 2014, up 31% quarter-over-quarter.
- 34 funds opened new Avadel Pharmaceuticals positions in Q4 2014 and 9 closed out, a net change of +25 holders.
- The largest Avadel Pharmaceuticals buyer in Q4 2014 was T. Rowe Price Associates, an estimated $9.51M added.
- The largest Avadel Pharmaceuticals seller in Q4 2014 was JP Morgan Chase, an estimated $18.3M sold.
Based on aggregated 13F filings for Q4 2014.